Reduced cardiovascular events in obese or overweight participants without diabetes.155Reduced HF hospitalisation, all-cause mortality, and atherosclerotic events in diabetic patients without HF.156Reduced body weight, HF symptoms and NT-proBNP levels, improved physical, and exercise function in non-diabetic HFpEF patients.164,165Not recommended for HFrEF due to its effect to elevate heart rate.168. This evidence concerns the gene NPPB and hydrops fetalis.